TAK - Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
2025-01-30 17:03:15 ET
Summary
- On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again.
- So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023.
- Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.
- In this article, you will learn five reasons why I believe Johnson & Johnson is an appealing stock for income-oriented investors.
Johnson & Johnson (NYSE: JNJ ) is a major player in the pharmaceutical industry, with a rich portfolio of medications widely used to treat various types of cancer, as well as autoimmune and neurological disorders....
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)